NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

OraSure Technologies, Inc. (OSUR) Stock Analysis

OraSure Technologies, Inc. (OSUR) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

OSUR

$3.48

−$0.10 (−2.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OSUR with… →

OSUR Key Statistics

As of Sep 4, 2026
Trading
Open
$3.55
Previous Close
$3.58
Day's Range
3.47–3.64
52-Week Range
2.08–4.58
Volume
304.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.99
Valuation
Market Cap
$240.01M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
6.19
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.14
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.69
Financials (FY)
Revenue (FY)
$115.02M−38.10%
Net Income (FY)
−$68.73M
Profit marginThe share of revenue left as profit after all costs and taxes.
−43.70%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.97M
1-Year Return
+10.48%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
488.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OSUR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+43.80%
2025−32.96%
2024−55.98%
2023+70.12%
2022−44.53%
2021−17.94%
2020+31.88%
2019−31.25%
2018−38.07%
2017+114.81%
2016 (partial year)+21.27%

As of September 4, 2026.

OSUR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$115.02M−$68.73M−59.8%
2024$185.83M−$19.50M−10.5%
2023$405.47M$53.66M13.2%
2022$387.48M−$17.13M−4.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$115.02M$48.20M−$68.12M−$68.73M−59.8%
2024$185.83M$79.39M−$23.86M−$19.50M−10.5%
2023$405.47M$171.65M$43.41M$53.66M13.2%
2022$387.48M$148.44M−$5.24M−$17.13M−4.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OSUR Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricOSURMedical Instruments & Supplies medianvs median
P/S ratio2.143.1733% below
Profit margin−43.70%0.85%44.6 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

OraSure Technologies, Inc. (OSUR) is capitalised at $240.01M on the latest close. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. The company reports 500 employees.

OSUR last closed at $3.48 on September 4, 2026. That is −$0.10 (−2.79%) against the previous close. Over the past 52 weeks the price has ranged from $2.08 to $4.58. The latest close sits 67.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $115.02M. Against the prior fiscal year total of $185.83M, that is a change of −38.10%. The same year closed with a net loss of $68.73M. Profit margin runs at −43.7%. That is 44.6 percentage points below the Medical Instruments & Supplies median of 0.85%. Trailing earnings per share are −0.69.

Across the 4 fiscal years on file, revenue moves from $387.48M in 2022 to $115.02M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 6.19. Measured against sales, the shares trade at 2.14 times revenue. On price-to-sales that is 32.71% below the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

The trailing one-year price return is +10.48%. Across 10 years the annualized return works out at −8.78%. The reported beta is 0.99. Annualized volatility over the trailing 10 years is 56.56%.

Growth & Income

The record shows no dividend for OSUR.

The strongest complete calendar year on file is 2017 at +114.81%; the weakest is 2024 at −55.98%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +43.80% year to date.

Peer Comparison

OraSure Technologies, Inc. (OSUR) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OraSure Technologies, Inc. OSUR $240.01M —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. OraSure Technologies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About OraSure Technologies, Inc.

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Visit website →